KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Exchange Rate Effect (2016 - 2025)

Acadia Pharmaceuticals has reported Exchange Rate Effect over the past 14 years, most recently at $7000.0 for Q4 2025.

  • Quarterly results put Exchange Rate Effect at $7000.0 for Q4 2025, up 111.67% from a year ago — trailing twelve months through Dec 2025 was $26000.0 (up 127.66% YoY), and the annual figure for FY2025 was $26000.0, up 127.66%.
  • Exchange Rate Effect for Q4 2025 was $7000.0 at Acadia Pharmaceuticals, down from $24000.0 in the prior quarter.
  • Over the last five years, Exchange Rate Effect for ACAD hit a ceiling of $24000.0 in Q2 2025 and a floor of -$60000.0 in Q4 2024.
  • Median Exchange Rate Effect over the past 5 years was $1500.0 (2021), compared with a mean of -$4055.6.
  • Biggest five-year swings in Exchange Rate Effect: crashed 950.0% in 2024 and later soared 700.0% in 2025.
  • Acadia Pharmaceuticals' Exchange Rate Effect stood at $1000.0 in 2021, then tumbled by 900.0% to -$8000.0 in 2022, then crashed by 50.0% to -$12000.0 in 2023, then plummeted by 400.0% to -$60000.0 in 2024, then soared by 111.67% to $7000.0 in 2025.
  • The last three reported values for Exchange Rate Effect were $7000.0 (Q4 2025), $24000.0 (Q2 2025), and -$5000.0 (Q1 2025) per Business Quant data.